Is retatrutide available to the public?

Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.

When might retatrutide receive FDA approval?

Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Home›Legal›Retatrutide in New York

Educational — Not Legal AdviceUpdated May 10, 2026

Retatrutide in New York: Legal Status & Provider Guide (2026)

Quick Answer

Retatrutide is a prescription substance in the United States. Retatrutide is an investigational triple-receptor agonist (GIP/GLP-1/glucagon) with no FDA approval. It cannot legally be compounded under federal law. Commercial availability outside of clinical trials is not authorized by the FDA. In New York, compounding is governed by the New York State Board of Pharmacy (NYSBP). New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.

Federal Legal Status

FDA Approval Status

Not FDA-approved. Retatrutide is in Phase III clinical trials as of 2026. No NDA filed.

Compounding Pharmacy Rules (Federal)

Retatrutide is not FDA-approved and is not on any bulk substances list for compounding. It is an investigational drug in active Phase III trials. Compounding pharmacies cannot legally compound retatrutide under federal law. Providers offering it outside of a formal clinical trial operate without federal regulatory authorization.

Also Known As

LY3437943

Primary Research Areas

Weight loss
Obesity management
Metabolic syndrome
Type 2 diabetes

New York Pharmacy Board & Compounding Rules

Regulator

New York State Board of Pharmacy (NYSBP)

Compounding Overview

New York has among the most stringent pharmacy and prescribing regulations in the country. The New York State Board of Pharmacy enforces USP 797 and 795 standards and requires all compounding pharmacies to meet detailed quality and documentation requirements. New York has been particularly active in enforcing against unapproved compounded medications. In-state telehealth peptide providers are subject to strict New York Medical Board oversight.

Notable Rules

New York requires compounding pharmacies to register separately for sterile compounding.
The New York Department of Health has enforcement authority over unlicensed pharmaceutical activity.
New York has stricter-than-federal requirements for documentation of medical necessity for compounded preparations.
Interstate prescribing into New York requires a New York state license.
New York and Pennsylvania maintain reciprocal pharmacy licensure recognition for some categories.

Prescribing Requirements in New York

New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.

About Retatrutide

Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase II trials reported average weight loss of approximately 24% at the highest dose over 48 weeks. Phase III trials are ongoing as of 2026.

For more research information, mechanism of action, and provider availability, see the Retatrutide research profile on PeptideBase.

Frequently Asked Questions

Is retatrutide available to the public?: Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.
When might retatrutide receive FDA approval?: Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Retatrutide Providers in New York

3 providers in the PeptideBase directory offer Retatrutide in New York. Always verify current offerings directly with the provider.

View all Retatrutide providers nationwide →

Retatrutide Legal Status in Other States

Pharmacy board rules and compounding regulations vary by state. Compare Retatrutide legal status across other major markets:

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: May 10, 2026.